Epi-Drugs and Epi-miRs: Moving Beyond Current Cancer Therapies

Reza Salarinia; Amirhossein Sahebkar; Mostafa Peyvandi; Hamid Reza Mirzaei; Mahmoud Reza Jaafari; Maryam Matbou Riahi; Hamed Ebrahimnejad; Javid Sadri Nahand; Jamshid Hadjati; Mobina Ostadi Asrami; Sara Fadaei; Rasoul Salehi; Hamed Mirzaei

doi:10.2174/1568009616666151207110143

ISSN: 1568-0096
E-ISSN: 1873-5576

Epi-Drugs and Epi-miRs: Moving Beyond Current Cancer Therapies
By Reza Salarinia, Amirhossein Sahebkar, Mostafa Peyvandi, Hamid Reza Mirzaei, Mahmoud Reza Jaafari, Maryam Matbou Riahi, Hamed Ebrahimnejad, Javid Sadri Nahand, Jamshid Hadjati, Mobina Ostadi Asrami, Sara Fadaei, Rasoul Salehi and Hamed Mirzaei
Source: Current Cancer Drug Targets, Volume 16, Issue 9, Nov 2016, p. 773 - 788
DOI: https://doi.org/10.2174/1568009616666151207110143
- Available online: 01 Nov 2016

Abstract

Epigenetic modifications determine phenotypic characteristics in a reversible, stable and genotype-independent manner. Epigenetic modifications mainly encompass CpG island methylation and histone modifications, both being important in the pathogenesis of malignancies. The reversibility of epigenetic phenomenon provides a suitable therapeutic option that is reactivation of epigenetically silenced tumor-suppressor genes. Inhibition of DNA methyltransferase, histone deacetylase and Aurora B kinase, individually or collectively, could feasibly prevent or reverse the impact of epigenetic silencing. MicroRNAs [miRNAs] are an important layer of epigenetic controlling of gene expression, and serve as diagnostic and prognostic biomarkers as well as treatment targets for several types of cancer. miRNAs are involved inepigenetically silencing or activation of genes, tumor suppressor genes and oncogenes, and their modulation opens new horizons for designing novel cancer therapeutic agents.

Article metrics loading...

/content/journals/ccdt/10.2174/1568009616666151207110143

2016-11-01

2025-09-04

From This Site

/content/journals/ccdt/10.2174/1568009616666151207110143

dcterms_title,dcterms_subject,pub_keyword

-contentType:Contributor -contentType:Concept -contentType:Institution

10

5

Full text loading...

/content/journals/ccdt/10.2174/1568009616666151207110143

Article Type: Research Article

Keyword(s): Cancer epigenetics; DNA methyltransferase inhibitor; Epi-drugs; Epi-miRs; Histone deacetylase inhibitor

Most Cited Most Cited RSS feed

- Luteolin, a Flavonoid with Potential for Cancer Prevention and Therapy
  
  Authors: Yong Lin, Ranxin Shi, Xia Wang and Han-Ming Shen
- The Role of Snail in EMT and Tumorigenesis
  
  Authors: Yifan Wang, Jian Shi, Kequn Chai, Xuhua Ying and Binhua P. Zhou
- The PTEN/PI3K/AKT Signalling Pathway in Cancer, Therapeutic Implications
  
  Authors: Amancio Carnero, Carmen Blanco-Aparicio, Oliver Renner, Wolfgang Link and Juan F.M. Leal
- Bortezomib as the First Proteasome Inhibitor Anticancer Drug: Current Status and Future Perspectives
  
  Authors: D. Chen, M. Frezza, S. Schmitt, J. Kanwar and Q. P. Dou
- P-glycoprotein Inhibition as a Therapeutic Approach for Overcoming Multidrug Resistance in Cancer: Current Status and Future Perspectives
  
  Authors: Ziyad Binkhathlan and Afsaneh Lavasanifar
- Taxanes: Microtubule and Centrosome Targets, and Cell Cycle Dependent Mechanisms of Action
  
  Authors: M. Abal, J.M. Andreu and I. Barasoain
- Paclitaxel Resistance: Molecular Mechanisms and Pharmacologic Manipulation
  
  Authors: R.Z. Yusuf, Z. Duan, D.E. Lamendola, R.T. Penson and M.V. Seiden
- The Role of Fibroblast Growth Factors in Tumor Growth
  
  Authors: M. Korc and R. E. Friesel
- Garlic [Allium sativum]: A Review of its Potential Use as an Anti-Cancer Agent
  
  Authors: M. Thomson and M. Ali
- Oxidative Stress and Cancer: The Role of Nrf2
  
  Authors: Soraya Sajadimajd and Mozafar Khazaei
More Less

Epi-Drugs and Epi-miRs: Moving Beyond Current Cancer Therapies

Abstract

Most Read This Month

Most Cited Most Cited RSS feed